亚洲精品久久无码2021,偷拍亚洲另类无码专区制服,亚洲欧美性都花花世界,国产熟女的精品视频大全,色偷偷2025免费视频观看,撅着大腚SXMV色香视频

Originial from: genomeweb

Natera announced last Friday that it has acquired cancer diagnostic firm Foresight Diagnostics for $275 million upfront. 

The deal includes an additional $175 million in earnouts tied to the achievement of revenue- and reimbursement-based milestones, Natera noted in a statement. 

Foresight uses its PhasED-Seq technology to develop circulating tumor-based minimal residual disease tests. The approach relies on phased variants — two or more single nucleotide variants that occur on the same DNA molecule — to detect ctDNA at greater sensitivity than other technologies, according to the company. It has reported performance with LOD95 of 0.3 parts per million and detection below 0.1 parts per million. 

Natera noted that the transaction combines Natera's commercial and operational infrastructure to deliver personalized MRD testing with Foresight's phased variant technology and leadership in lymphoma. The deal also builds on Natera's broad intellectual property portfolio for tumor-informed and personalized MRD products and will accelerate MRD adoption in lymphoma and other solid tumor types, Natera said. 

The integration of phased variants into the Signatera platform "will further differentiate and strengthen test performance across solid tumors," Natera said. The enhanced version of the platform is available immediately for research use for biopharmaceutical and academic partners and is expected to be launched in 2026 for clinical use. 

According to an investor note from Leerink Partners analyst Puneet Souda, the integration of PhaseED-Seq technology "lifts sensitivity for Signatera meaningfully on all solid tumors and helps [Natera] expand into the lymphoma market," which accounts for about 80,000 patients annually. 

Foresight also has "clinical research momentum" in B-cell lymphomas, providing data for the inclusion of ctDNA MRD into the National Comprehensive Cancer Network Clinical Practice Guidelines for diffuse large B-cell lymphoma, Natera said. The firm's Clarity MRD assay for lymphoma is also being used in three prospective MRD-driven clinical trials and will continue to support clinical trials, translational research, and future applications, Natera added. 

"This acquisition reinforces Natera’s position at the forefront of precision oncology,” Natera CEO Steve Chapman said in a statement. "Foresight’s phased variant technology and leadership in lymphoma complement Natera’s strong capabilities in personalized MRD testing, improving the value we can deliver to patients, clinicians, biopharma partners, and the broader healthcare system."

Souda noted that Natera "generally has a conservative approach to M&A because they believe it is usually cheaper to build versus buy," adding that "this was an unusual circumstance where [management] believed Foresight's tech was so differentiated, and its IP so strong, that acquisition made sense."

Source: Natera Acquires Foresight Diagnostics for $275M